Citadel Advisors’s Usana Health Sciences USNA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$176K Sell
10,100
-2,700
-21% -$53.6K ﹤0.01% 11540
2025
Q4
$251K Sell
12,800
-100
-0.8% -$2.08K ﹤0.01% 10541
2025
Q3
$355K Buy
+12,900
New +$397K ﹤0.01% 9955
2025
Q2
Sell
-7,200
Closed -$194K 15228
2025
Q1
$194K Buy
7,200
+5,100
+243% +$161K ﹤0.01% 10499
2024
Q4
$75.4K Sell
2,100
-700
-25% -$26.2K ﹤0.01% 11862
2024
Q3
$106K Buy
2,800
+100
+4% +$4.11K ﹤0.01% 11025
2024
Q2
$122K Sell
2,700
-7,100
-72% -$327K ﹤0.01% 10635
2024
Q1
$475K Buy
9,800
+9,300
+1,860% +$455K ﹤0.01% 8520
2023
Q4
$26.8K Sell
500
-1,000
-67% -$50.6K ﹤0.01% 12365
2023
Q3
$87.9K Buy
1,500
+800
+114% +$50K ﹤0.01% 11053
2023
Q2
$44.1K Sell
700
-10,900
-94% -$694K ﹤0.01% 11951
2023
Q1
$730K Buy
11,600
+8,500
+274% +$507K ﹤0.01% 7472
2022
Q4
$165K Buy
+3,100
New +$168K ﹤0.01% 10455
2021
Q4
Sell
-3,800
Closed -$350K 14803
2021
Q3
$350K Sell
3,800
-1,500
-28% -$144K ﹤0.01% 10718
2021
Q2
$543K Buy
5,300
+500
+10% +$50.2K ﹤0.01% 9893
2021
Q1
$468K Buy
4,800
+1,400
+41% +$127K ﹤0.01% 9816
2020
Q4
$262K Buy
+3,400
New +$263K ﹤0.01% 9302
2020
Q3
Sell
-4,700
Closed -$345K 10774
2020
Q2
$345K Sell
4,700
-4,500
-49% -$353K ﹤0.01% 7690
2020
Q1
$531K Buy
9,200
+4,500
+96% +$313K ﹤0.01% 6373
2019
Q4
$369K Sell
4,700
-500
-10% -$36.8K ﹤0.01% 7269
2019
Q3
$356K Buy
5,200
+2,100
+68% +$141K ﹤0.01% 7310
2019
Q2
$246K Buy
+3,100
New +$246K ﹤0.01% 7893
2019
Q1
Sell
-3,000
Closed -$353K 9894
2018
Q4
$353K Sell
3,000
-100
-3% -$11.6K ﹤0.01% 6982
2018
Q3
$374K Sell
3,100
-3,200
-51% -$397K ﹤0.01% 7206
2018
Q2
$726K Buy
+6,300
New +$689K ﹤0.01% 5763

Other funds holding USNA

Citadel Advisors's USNA Position: Q1 2026 in Review

Citadel Advisors reduced its Usana Health Sciences (USNA) stake by 73% in Q1 2026, selling an estimated $2.19M and leaving 41,148 shares worth $719K. The position accounts for ﹤0.01% of the portfolio, ranked #8442.

Citadel Advisors first reported a position in USNA in Q2 2013 and has held it in 45 quarters since. The position peaked at $13.8M in Q1 2019. 139 funds tracked by Wall St. Rank hold USNA as of Q1 2026.

  • Citadel Advisors held 41,148 shares of Usana Health Sciences worth $719K as of Q1 2026.
  • Citadel Advisors sold 110,268 Usana Health Sciences shares in Q1 2026, an estimated $2.19M.
  • Usana Health Sciences made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #8442 holding.
  • Citadel Advisors first reported a position in Usana Health Sciences in Q2 2013 and has held it in 45 quarters since.
  • Citadel Advisors's Usana Health Sciences position peaked at $13.8M in Q1 2019.
  • 139 funds tracked by Wall St. Rank held Usana Health Sciences as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.